Table 1.
Characteristics of the included studies.
| Author | Country | Patients | Duratin | Study type | NOS score | ki-67 | HR and 95% CI | Survival analysis | |
|---|---|---|---|---|---|---|---|---|---|
| Rui et al. (16) | Portugal | 82 | 1990-1996 | Retrospective | 8 | 14% | Calculated | OS | |
| Stefan et al. (17) | American&Spain | 66 | 1991-2016 | Retrospective | 7 | 10% | Reported | PFS | |
| Ting et al. (18) | American | 114 | 2002-2008 | Prospective | 7 | 25% | Reported | OS | |
| Eric M et al. (19) | American | 68 | 2002-2015 | Prospective | 6 | 25% | Reported | OS;RFS | |
| O Ben-Izhak et al. (20) | Israel | 30 | NA | Retrospective | 7 | 40% | Calculated | OS | |
| Oddbjørn et al. (21) | Norway | 202 | 1981-1997 | Retrospective | 8 | 16% | Reported | OS | |
| ALEKSANDER et al. (22) | Poland | 93 | 1983-1991 | Retrospective | 7 | 20% | Calculated | OS | |
| Vivi Ann et al. (23) | Norway | 47 | NA | Retrospective | 7 | 5% | Reported | RFS | |
| Nicholas et al. (24) | American | 66 | 1991-2013 | Retrospective | 7 | 10% | Reported | PFS | |
| Philipp et al. (25) | Germany | 161 | 1980-2008 | Retrospective | 7 | 20% | Reported | OS | |
CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; RFS, relapse-free survival. NA, not available.